Vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
Life of this patent
Estimating the term…
Abstract
The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
Claims9
A method of immunising a human host against disease caused by Streptococcus pneumoniae infection comprising administering to the host an immunoprotective dose of a multivalent immunogenic composition comprising S. pneumoniae capsular saccharide conjugates of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F and a pharmaceutically acceptable excipient, wherein each of the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 22F and 23F is conjugated to a carrier protein independently selected from the group consisting of tetanus toxoid (TT), diphtheria toxoid (DT), CRM-197, fragment C of TT, PhtD, PhtBE, or PhtDE fusions, detoxified pneumolysin and protein D, and wherein the 19A and 19F is each independently conjugated to diphtheria toxoid or CRM197, wherein 19A capsular saccharide is directly conjugated to the carrier protein.
Dependencies are inferred from the claim text.